Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 12;9(9):e002754. doi: 10.1136/jitc-2021-002754

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Spatial and temporal distribution of neoantigen-specific TCRs as determined by TCR-β sequencing. (A) Productive frequency of CDR3 rearrangements (amino acid) calculated as the number of sequencing templates divided by the sum of template counts for all productive rearrangements in M_Int and M_Lung. Scatter plot dataset was generated with adaptive Biotechnologies ImmunoSEQ analysis software. (B) Distribution of neoantigen-specific TCRs in resected tumor and lymph node tissues. Percentages indicate frequency of identified neoantigen-specific TCRs in analyzed tissue repertoire as inferred from TCR-β deep sequencing data. (C) Productive frequency expressed as percentage of neoantigen-specific clonotypes in peripheral blood at different time points after first treatment with ipilimumab. TCR, T-cell receptor.